[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE055000T2 - Étvágy stimulálása, tömegvesztés kézbentartása és anorexia kezelése kutyák és macskák esetében - Google Patents

Étvágy stimulálása, tömegvesztés kézbentartása és anorexia kezelése kutyák és macskák esetében

Info

Publication number
HUE055000T2
HUE055000T2 HUE16756426A HUE16756426A HUE055000T2 HU E055000 T2 HUE055000 T2 HU E055000T2 HU E16756426 A HUE16756426 A HU E16756426A HU E16756426 A HUE16756426 A HU E16756426A HU E055000 T2 HUE055000 T2 HU E055000T2
Authority
HU
Hungary
Prior art keywords
anorexia
appetite
cats
dogs
stimulation
Prior art date
Application number
HUE16756426A
Other languages
English (en)
Inventor
William Buhles
Richard Cortez
Kristin Maas
Geeta Srivastava
Daniel Perez
Original Assignee
Dechra Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dechra Ltd filed Critical Dechra Ltd
Publication of HUE055000T2 publication Critical patent/HUE055000T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Finger-Pressure Massage (AREA)
HUE16756426A 2015-02-27 2016-02-26 Étvágy stimulálása, tömegvesztés kézbentartása és anorexia kezelése kutyák és macskák esetében HUE055000T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562126188P 2015-02-27 2015-02-27

Publications (1)

Publication Number Publication Date
HUE055000T2 true HUE055000T2 (hu) 2021-10-28

Family

ID=56789326

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16756426A HUE055000T2 (hu) 2015-02-27 2016-02-26 Étvágy stimulálása, tömegvesztés kézbentartása és anorexia kezelése kutyák és macskák esetében

Country Status (14)

Country Link
US (1) US10603272B2 (hu)
EP (1) EP3261645B1 (hu)
JP (1) JP6876003B2 (hu)
AU (1) AU2016222550B2 (hu)
CA (1) CA3013771C (hu)
DK (1) DK3261645T3 (hu)
ES (1) ES2874549T3 (hu)
HR (1) HRP20211040T1 (hu)
HU (1) HUE055000T2 (hu)
PL (1) PL3261645T3 (hu)
PT (1) PT3261645T (hu)
RS (1) RS62055B1 (hu)
SI (1) SI3261645T1 (hu)
WO (1) WO2016138357A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062621A1 (en) 2015-02-24 2022-03-03 Elira, Inc. Electrical Stimulation-Based Weight Management System
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US10463854B2 (en) 2015-02-24 2019-11-05 Elira, Inc. Systems and methods for managing symptoms associated with dysmenorrhea using an electro-dermal patch
WO2018081423A1 (en) * 2016-10-26 2018-05-03 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
CN112107584A (zh) * 2020-07-17 2020-12-22 上海信元动物药品有限公司 治疗宠物恶心呕吐、食欲减退的米氮平制剂组成及其工艺

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431663B1 (en) 1989-12-06 1994-01-12 Akzo Nobel N.V. Stabilized solutions of psychotropic agents
EP0813873B1 (en) 1996-06-19 2002-02-13 Akzo Nobel N.V. Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
EP1829539A3 (en) 1996-11-05 2008-02-20 HEADEXPLORER ApS A method for treating tension-type headache
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
PL192272B1 (pl) 1997-11-14 2006-09-29 Akzo Nobel Nv Zastosowanie mirtazapiny
ATE324110T1 (de) 1998-02-27 2006-05-15 Univ Illinois Stoffe mit serotoninartiger wirkung zur behandlung der schlafapnoe
DE69913116T2 (de) 1998-04-02 2004-06-03 Akzo Nobel N.V. Orale flüssige lösung enthaltend das antidepressivum mirtazapine
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
EP1178805A4 (en) 1999-04-19 2004-11-24 Teva Pharma NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS
WO2000063185A1 (en) 1999-04-19 2000-10-26 Teva Pharmaceutical Industries Ltd. Novel synthesis of piperazine ring
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
CN1355698A (zh) 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
TWI256309B (en) 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
WO2001038329A1 (fr) 1999-11-24 2001-05-31 Sumika Fine Chemicals Co., Ltd. Cristaux de mirtazapine anhydre et leur procede d'obtention
WO2001042239A1 (fr) 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Procede de preparation d'un compose pyridinemethanol
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
ATE317261T1 (de) 2000-02-11 2006-02-15 Akzo Nobel Nv Verwendung von mirtazapin zur behandlung von schlafstörungen
US7678387B2 (en) 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6375982B1 (en) 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US20020072602A1 (en) 2000-07-07 2002-06-13 Claude Singer Micronized mirtazapine
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US6660730B2 (en) 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
ES2296893T3 (es) 2001-02-12 2008-05-01 N.V. Organon Uso de mirtazapina para el tratamiento de la depresion severa en un paciente humano y portador del gen de la apolipoproteina e4.
KR20030078086A (ko) 2001-03-01 2003-10-04 테바 파마슈티컬 인더스트리즈 리미티드 미르타자핀 중간체의 제조방법
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
ITMI20011446A1 (it) 2001-07-06 2003-01-06 Altergon Sa Composizioni farmaceutiche di principi attivi suscettibili di somministrazione illecita
WO2007064311A1 (en) 2001-07-10 2007-06-07 Teva Pharmaceutical Industries Ltd. Micronized mirtazapine
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
EP1941878A1 (en) 2002-01-10 2008-07-09 Biovail Laboratories International Srl Sedative non-benzodiazepine formulations
AU2003213787A1 (en) 2002-03-06 2003-09-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US20030194420A1 (en) 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
FR2842734A1 (fr) 2002-07-24 2004-01-30 Ethypharm Sa Procede pour diminuer la variabilite de la biodisponibilite d'un medicament a administration orale et compositions pharmaceutiques a administration orale
US20120156144A1 (en) 2002-10-25 2012-06-21 Foamix Foamable Compositions, Kits and Methods for Hyperhidrosis
EP1562557B2 (en) 2002-11-01 2016-11-16 University of Medicine and Dentistry of New Jersey Geodate delivery vehicles
US20050013845A1 (en) 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20040192754A1 (en) 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
WO2004100857A2 (en) 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
US7041826B2 (en) 2003-06-02 2006-05-09 Aurobindo Pharma Ltd. Process for preparing 1-methyl-3-phenylpiperazine using a novel intermediate
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
AU2003903597A0 (en) 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
WO2005016321A1 (en) 2003-08-15 2005-02-24 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20050112196A1 (en) 2003-10-07 2005-05-26 Jianbo Xie Rapidly disintegrating formulation
US20070298107A1 (en) 2003-11-25 2007-12-27 Aurobindo Pharma Ltd. Pharmaceutical Compositions of Mirtazapine
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005089511A2 (en) 2004-03-19 2005-09-29 Transform Pharmaceuticals, Inc. Novel pharmaceutical forms, and methods of making and using the same
TW200538100A (en) 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
DE102004034043A1 (de) 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
ES2246161B1 (es) 2004-07-22 2007-04-01 Medichem, S.A. Proceso mejorado para la fabricacion de mirtazapina.
WO2006017861A2 (en) 2004-08-13 2006-02-16 Omeros Corporation Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
TW200631584A (en) 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
WO2006069030A1 (en) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
WO2006088305A1 (en) 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Gastric-retentive controlled release mono-matrix tablet
EP1879027B1 (en) 2005-04-27 2013-06-12 CytoPathfinder, Inc. Agent for preventing and treating pancreatitis
US20090306046A1 (en) 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
AU2006264407B2 (en) 2005-07-04 2012-08-30 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
WO2007012154A1 (en) 2005-07-27 2007-02-01 Carlos Henrique Horta Lima Pharmaceutical preparation containing an acetylcholinesterase ihibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties.
WO2007019880A1 (en) 2005-08-18 2007-02-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2007035003A1 (ja) 2005-09-26 2007-03-29 Sumitomo Chemical Company, Limited 光学活性なピペラジン化合物の製造方法
US20070092586A1 (en) 2005-10-26 2007-04-26 Alamo Pharmaceuticals Compositions and methods for the administration psychotropic drugs which modulate body weight
JP2009514946A (ja) 2005-11-06 2009-04-09 ブレイン ウォッチ エルティディ 磁気共鳴画像／分光手段およびその方法
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
US7541371B2 (en) 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease
CA2644985A1 (en) 2006-03-06 2007-09-13 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
FR2900339B1 (fr) 2006-04-28 2008-07-25 Univ Claude Bernard Lyon I Eta Utilisation d'un compose qui induit une augmentation du taux de serotonine libre dans l'organisme, pour la preparation d'un medicament destine a traiter des degenerescences du muscle squelettique
US20070270413A1 (en) 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200808804A (en) 2006-05-22 2008-02-16 Organon Nv Mirtazapine for the treatment of neuropathic pain
WO2007146331A1 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
DE102006027792A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
US20080014252A1 (en) 2006-07-14 2008-01-17 Delprete Keith Topical compositions with long lasting effect
WO2008060397A2 (en) 2006-11-03 2008-05-22 Noven Therapeutics, Llc Method of treating thermoregulatory disfunction
JP2010510290A (ja) 2006-11-22 2010-04-02 ナームローゼ・フエンノートチヤツプ・オルガノン ミルタザピンのための膣送達系
WO2008104996A2 (en) 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
JP5192707B2 (ja) 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
CA2684021A1 (en) 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of an enantiomer of a tetracyclic benzazepine
CA2682932A1 (en) 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of an enantiomerically pure benzazepine
US20080255348A1 (en) 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
US7994314B2 (en) 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
WO2009018088A2 (en) 2007-08-01 2009-02-05 Link Medicine Corporation Imaging of alpha-synuclein
WO2009055001A2 (en) 2007-10-23 2009-04-30 Fred Hutchinson Cancer Research Center Methods of treating aging and methods of screening candidate agents therefor
NZ585033A (en) * 2007-11-02 2011-12-22 Acrux Dds Pty Ltd Transdermal delivery system
BRPI0908539B8 (pt) 2008-02-28 2021-05-25 Scherer Technologies Llc R P processo para a preparação de uma forma sólida rápida de dosagem da dispersão, oral de alprazolam
WO2010046851A1 (en) 2008-10-22 2010-04-29 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
KR20110110297A (ko) 2009-01-09 2011-10-06 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 불소 함유 화합물 및 이의 사용방법
WO2010148519A1 (en) 2009-06-25 2010-12-29 Queen's University At Kingston Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist
WO2011091050A1 (en) 2010-01-19 2011-07-28 Nektar Therapeutics Oligomer-tricyclic conjugates
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
EP2377522B1 (en) 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
WO2012026963A2 (en) 2010-08-23 2012-03-01 Darren Rubin Systems and methods of aerosol delivery with airflow regulation
DE102010049706A1 (de) 2010-10-28 2012-05-03 Hexal Ag Herstellung orodispersibler Filme
EP2650019B1 (en) 2010-12-07 2015-08-05 Yutoku Pharmaceutical Industries Co., Ltd. Noradrenergic and specific serotonergic antidepressant-containing transdermal patch
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
GB2503187A (en) 2011-09-15 2013-12-25 Univ Sussex Composition for use in the treatment of neurodevelopmental disorders
AU2012327191A1 (en) * 2012-04-17 2013-10-31 Colorado State University Research Foundation Mirtazapine as an appetite stimulant for cats
WO2013183407A1 (ja) * 2012-06-05 2013-12-12 祐徳薬品工業株式会社 ミルタザピン含有経皮吸収型貼付製剤
EP2690102A1 (en) 2012-07-24 2014-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bicyclic aza-amides for treatment of psychiatric disorders
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US20140271727A1 (en) 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
EP3003031A1 (en) 2013-06-04 2016-04-13 Vyome Biosciences Pvt Ltd Coated particles and compositions comprising same
EP2856934A1 (en) 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression
GB201320675D0 (en) 2013-11-22 2014-01-08 Univ Nottingham Composition
EP3076967B1 (en) 2013-12-03 2021-07-28 Intra-Cellular Therapies, Inc. Methods for treating residual symptoms of schizophrenia
FR3015289B1 (fr) 2013-12-20 2017-01-13 Virbac Mirtazapine injectable

Also Published As

Publication number Publication date
AU2016222550A1 (en) 2017-08-31
JP2018507911A (ja) 2018-03-22
EP3261645B1 (en) 2021-04-28
DK3261645T3 (da) 2021-06-07
SI3261645T1 (sl) 2021-08-31
WO2016138357A1 (en) 2016-09-01
AU2016222550B2 (en) 2020-07-16
ES2874549T3 (es) 2021-11-05
US20180021251A1 (en) 2018-01-25
PL3261645T3 (pl) 2021-12-06
PT3261645T (pt) 2021-06-17
RS62055B1 (sr) 2021-07-30
US10603272B2 (en) 2020-03-31
EP3261645A4 (en) 2018-08-08
CA3013771C (en) 2024-01-02
CA3013771A1 (en) 2016-09-01
EP3261645A1 (en) 2018-01-03
HRP20211040T1 (hr) 2021-10-01
JP6876003B2 (ja) 2021-05-26

Similar Documents

Publication Publication Date Title
IL267319A (en) Management of a grant
PT3261645T (pt) Estimulação do apetite, gestão da perda de peso, e tratamento da anorexia em cães e gatos
ZA201606158B (en) Treatment of metabolic disorders in equine animals
GB201418007D0 (en) Animal skin substrate Treatment apparatus and method
GB201418006D0 (en) Animal skin substrate treatment apparatus and method
EP3119188C0 (en) SYSTEM AND METHOD FOR TREATING FARM ANIMALS
PL3096765T3 (pl) Leczenie zaburzeń metabolicznych u zwierząt psowatych
GB201411194D0 (en) Animal feed and aqua feed
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
PL3307058T3 (pl) Zwijana smycz dla zwierząt i sposób jej obsługi
GB201519200D0 (en) Skin care composition and method thereof
GB201700661D0 (en) Power harvesting apparatus and design metho
HK1259451A1 (zh) 護膚組合物及其方法
GB201508219D0 (en) Skin and muscle stimulation apparatus
HK1213829A1 (zh) 分形刺激方法及設備
ZA201703052B (en) Animal model for dry eye and methods of use of such animals
PL3128838T3 (pl) Stymulatory roślin, ich zastosowanie i sposób stymulacji roślin
IL234889A0 (en) Wastewater treatment from livestock farming
EP3349568A4 (en) DEVICE FOR VOLUNTARY LIFTING OF WEIGHTS OF ANIMAL AND METHOD THEREFOR
HUE050795T2 (hu) Eljárás állati eledel elõállítására és annak alkalmazása
AU2014904293A0 (en) Treated Animal Litter and Bedding
SG10201401461SA (en) Livestock treatment method and apparatus
ZA201402610B (en) Livestock treatment method and apparatus
AU2015900923A0 (en) Bird Saver Net - A removable and transportable Safety Net for Bird Cage & Aviary Doors
GB201519207D0 (en) Skin care composition and method thereof